IP Library Patent Application 14491907
Patent Application
App. No. 14/491,907

METHOD OF TREATING BLURRED VISION AND OTHER CONDITIONS OF THE EYE WITH CYCLOSPORIN COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/491,907
Abstract

Disclosed herein is a method of treating blurred vision, of increasing keratocyte density, of increasing goblet cell density, and of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to the affected eye of an individual.

Claims (8)

1 . A method of increasing keratocyte density, the method comprising administering a cyclosporin composition to an eye of a subject having keratocyte loss or who would otherwise benefit from increased keratocyte density.

2 . The method of claim 1 , wherein the cyclosporin composition comprises cyclosporin A at a concentration from about 0.01% (w/v) to about 0.05% (w/v).

3 . A method of increasing goblet cell density, the method comprising administering a cyclosporin composition to an eye of a subject having goblet cell loss or who would otherwise benefit from increased goblet cell density.

4 . The method of claim 3 , wherein the cyclosporin composition comprises cyclosporin A at a concentration from about 0.01% (w/v) to about 0.05% (w/v).

5 . A method of treating psychological distress following surgery on the eye, the method comprising administering a cyclosporin composition to an eye of a subject in need of such treatment.

6 . The method of claim 5 , wherein the cyclosporin composition comprises cyclosporin A at a concentration from about 0.01% (w/v) to about 0.05% (w/v).

7 . A method of treating a patient having sensitivity to light, the method comprising topically administering a cyclosporin composition to an eye of a patient in need of such treatment.

8 . The method of claim 7 , wherein the cyclosporin composition comprises cyclosporin A at a concentration from about 0.01% (w/v) to about 0.05% (w/v).

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2017
From: ALLERGAN, INC.
To: SAINT REGIS MOHAWK TRIBE
Reel/Frame 043830/0446 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 20, 2015
From: SCHIFFMAN, RHETT M.
To: ALLERGAN, INC.
Reel/Frame 034760/0602 →